ISTH 2023 | A novel humanized anti-ADAMTS13 antibody for acquired Von Willebrand disease
Shannen Deconinck, PhD, KU Leuven Kulak Kortrijk, Kortrijk, Belgium, discusses recent research evaluating the therapeutic efficacy of a novel humanized anti-ADAMTS13 antibody for left ventricular assist device (LVAD)-induced acquired von Willebrand disease (vWD). Gastrointestinal bleeding is a major complication for patients with LVADs and has been linked to an acquired defect in the von Willebrand factor (vWF), which can be excessively cleaved under pathological sheer stress. Dr Deconinck explains how inhibiting ADAMTS13, a vWF-cleaving protease, using a novel humanized antibody could treat bleeding episodes in patients during the duration of LVAD support. This interview took place at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Montréal, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
